Pfizer shelves haemophilia gene therapy Beqvez

Pfizer shares surged 8.6% to Rs 4,448.35 after announcing a marketing and supply agreement with Mylan Pharmaceuticals for ...
Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.
Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...
Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...
Supporting Rapid Innovation through the PACT Initiative. Pfizer has focused on scientific innovation as a core value since it ...
PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.
Summit's Co-CEOs, Bob Duggan and Dr. Maky Zanganeh, expressed optimism about the collaboration's ability to accelerate the ...
An archived Facebook post claimed that Pfizer has released a list of side effects for COVID vaccine. The claim by the user is ...